Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F mutation in patients with portal vein thrombosis.

Digestive diseases and sciences - 1 Oct 2008

Bayraktar Yusuf, Harmanci Ozgur, Büyükasik Yahya, Shorbagi Ali Ibrahim, Sungur Aysegul Hasegeli, Boylu Cemaliye Akyerli, Gürgey Aytemiz, Balkanci Ferhun

Abstract excerpt

In a retrospective cohort, we investigated the presence of the JAK2V617F mutation in chronic non-cirrhotic portal vein thrombosis (PVT) patients, irrespective of the presence or absence of myeloproliferative diseases (MPDs). We identified 25 patients in whom thrombophilia workup was completed. The diagnoses of MPDs were made according to the World Health Organization (WHO) criteria. JAK2V617F mutation analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Disease
Share to Homozygote

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Myeloproliferative Disorders

Share to Portal Vein

Share to Venous Thrombosis

Share to World Health Organization

Source

Identifiers

PMID: 18343999
DOI: 10.1007/s10620-008-0225-y

Genes

JAK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F mutation in patients with portal vein thrombosis.PMID 18343999Read ↗

JAK2V617F mutation in patients with splanchnic vein thrombosis.Semantic proximity Read ↗

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.Semantic proximity Read ↗

Janus Kinase-2 Mutation Associated Portal Vein Thrombosis Complicating Liver Cirrhosis and Hepatocellular Carcinoma.Semantic proximity Read ↗

The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.Semantic proximity Read ↗

Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.Semantic proximity Read ↗

Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.Semantic proximity Read ↗

Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.Semantic proximity Read ↗

Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.Semantic proximity Read ↗

Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.Semantic proximity Read ↗

Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.Semantic proximity Read ↗

Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.Semantic proximity Read ↗

The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.